Can a new Omega-3 pill protect aging brains?

NCT ID NCT06933095

Recruiting now Disease control Sponsor: University of Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special omega-3 supplement called Lysoveta can deliver more DHA to the brain than standard fish oil. Researchers will measure DHA levels in spinal fluid and blood, along with memory and thinking tests, in 153 older adults with early signs of memory decline. The goal is to see if this approach improves brain health and slows cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lysoveta (LPC-EPA+DHA) capsules
What this could lead to: If successful, this could point toward a more effective way to deliver omega-3s to the brain, potentially slowing cognitive decline in older adults.
What could go wrong: This is an early-stage trial with 153 participants, so results may not apply to everyone. The supplement may not significantly improve memory or biomarkers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DECLINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE DECLINE DHA CNS DELIVERY ELDERY PEOPLE MEMORY DECLINE

Contacts and locations

Locations

University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
RECRUITING

Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.